CL2017000244A1 - Formulaciones de compuestos biológicos para instilación intravesical. - Google Patents

Formulaciones de compuestos biológicos para instilación intravesical.

Info

Publication number
CL2017000244A1
CL2017000244A1 CL2017000244A CL2017000244A CL2017000244A1 CL 2017000244 A1 CL2017000244 A1 CL 2017000244A1 CL 2017000244 A CL2017000244 A CL 2017000244A CL 2017000244 A CL2017000244 A CL 2017000244A CL 2017000244 A1 CL2017000244 A1 CL 2017000244A1
Authority
CL
Chile
Prior art keywords
formulations
biological compounds
intravesical instillation
intravesical
instillation
Prior art date
Application number
CL2017000244A
Other languages
English (en)
Inventor
Patrick M Hughes
Eric A Forssen
David C Rupp
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2017000244A1 publication Critical patent/CL2017000244A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>SE DESCRIBEN FORMULACIONES FARMACÉUTICAS QUE COMPRENDEN UN DERIVADO CLOSTRIDIAL Y UN AGENTE PERMEABILIZANTE PARA INSTALACIÓN INTRAVESICAL.</p>
CL2017000244A 2014-07-31 2017-01-30 Formulaciones de compuestos biológicos para instilación intravesical. CL2017000244A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462031302P 2014-07-31 2014-07-31

Publications (1)

Publication Number Publication Date
CL2017000244A1 true CL2017000244A1 (es) 2017-10-13

Family

ID=53801236

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000244A CL2017000244A1 (es) 2014-07-31 2017-01-30 Formulaciones de compuestos biológicos para instilación intravesical.

Country Status (17)

Country Link
US (2) US20160030570A1 (es)
EP (2) EP3747427A1 (es)
JP (3) JP6585157B2 (es)
KR (2) KR20170038030A (es)
CN (1) CN106573041A (es)
AU (2) AU2015296256A1 (es)
BR (1) BR112017001888A2 (es)
CA (1) CA2955492A1 (es)
CL (1) CL2017000244A1 (es)
CO (1) CO2017001712A2 (es)
DK (1) DK3174523T3 (es)
ES (1) ES2821731T3 (es)
IL (1) IL250086B (es)
PH (1) PH12017500178A1 (es)
RU (2) RU2720991C2 (es)
SG (1) SG11201700736YA (es)
WO (1) WO2016019180A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161970B2 (en) * 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
JP7253038B2 (ja) * 2019-03-28 2023-04-05 株式会社ジーシー 歯科用付加型シリコーン組成物
RU2743805C1 (ru) * 2020-06-26 2021-02-26 Государственное бюджетное учреждение здравоохранения Свердловской области "Центр специализированных видов медицинской помощи "Уральский институт травматологии и ортопедии имени В.Д. Чаклина" (ГБУЗ СО "ЦСВМП "УИТО им. В.Д. Чаклина") Способ лечения нейрогенного мочевого пузыря
RU2751649C1 (ru) * 2020-08-24 2021-07-15 Наталья Геннадиевна Галкина Способ лечения и профилактики цистита
KR102940220B1 (ko) * 2021-02-08 2026-03-17 주식회사 대웅 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물
WO2022214964A2 (en) * 2021-04-06 2022-10-13 Connectomica Spa. Selective connexin hemichannel blockers as therapeutic compounds and methods for treating inflammatory diseases
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7449192B2 (en) 1997-07-15 2008-11-11 The Regents Of The University Of Colorado Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction
US9066943B2 (en) 1997-07-15 2015-06-30 The Regents Of The University Of Colorado Use of botulinum toxin therapy for treatment of urological neurological conditions
EP2267008B1 (en) 1999-08-25 2014-07-02 Allergan, Inc. Activatable recombinant neurotoxins
GB0018527D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Composition
JP4981280B2 (ja) 2005-08-23 2012-07-18 本田技研工業株式会社 燃料電池
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
MY155049A (en) 2008-03-14 2015-08-28 Allergan Inc Immuno-based botolinum toxin serotype a activity assay
AU2009339292B2 (en) * 2008-12-10 2016-01-21 Allergan, Inc. Clostridial toxin pharmaceutical compositions
LT2379104T (lt) * 2008-12-31 2018-04-10 Revance Therapeutics, Inc. Injekcinės botulino toksino vaisto formos
JP5826635B2 (ja) 2009-03-13 2015-12-02 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 免疫系調節エンドペプチターゼ活性アッセイ
KR102017327B1 (ko) 2009-03-13 2019-09-03 알러간, 인코포레이티드 면역 기반 보툴리눔 독소 혈청형 ａ 활성 검정에 유용한 세포
JP2013514091A (ja) 2009-12-16 2013-04-25 アラーガン、インコーポレイテッド 組込型プロテアーゼ切断部位結合ドメインを含む改変クロストリジウム毒素
US10471150B2 (en) * 2010-01-20 2019-11-12 Urogen Pharma Ltd. Material and method for treating internal cavities
BR112012029666A2 (pt) 2010-05-20 2020-10-06 Allergan, Inc. toxinas clostridiais degradáveis
US20120189677A1 (en) * 2011-01-20 2012-07-26 Stephen Tonge Formulations
DK2836200T3 (da) * 2012-04-08 2020-09-21 Urogen Pharma Ltd Termoreversible hydrogelpræparater til anvendelse i behandlingen af lidelser i urothelium
RU2535115C1 (ru) * 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
US11182864B1 (en) 2015-07-13 2021-11-23 David C. Fox Non-sequential restaurant order system and method

Also Published As

Publication number Publication date
EP3747427A1 (en) 2020-12-09
CO2017001712A2 (es) 2017-05-19
US20230256097A1 (en) 2023-08-17
AU2020250260A1 (en) 2020-11-05
KR20170038030A (ko) 2017-04-05
AU2015296256A1 (en) 2017-03-02
DK3174523T3 (da) 2020-09-28
JP2017522344A (ja) 2017-08-10
IL250086B (en) 2020-11-30
RU2020115111A (ru) 2020-06-10
ES2821731T3 (es) 2021-04-27
WO2016019180A1 (en) 2016-02-04
RU2720991C2 (ru) 2020-05-15
JP6585157B2 (ja) 2019-10-02
RU2017103978A3 (es) 2019-01-24
BR112017001888A2 (pt) 2017-11-28
PH12017500178A1 (en) 2017-06-28
CA2955492A1 (en) 2016-02-04
JP2020055798A (ja) 2020-04-09
KR20220048046A (ko) 2022-04-19
SG11201700736YA (en) 2017-02-27
CN106573041A (zh) 2017-04-19
RU2017103978A (ru) 2018-08-28
US20160030570A1 (en) 2016-02-04
JP2022081521A (ja) 2022-05-31
EP3174523B1 (en) 2020-07-01
IL250086A0 (en) 2017-03-30
EP3174523A1 (en) 2017-06-07

Similar Documents

Publication Publication Date Title
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CO2017001712A2 (es) Formulaciones de compuestos biológicos para instilación
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112018072663A2 (pt) moduladores da via integrada ao estresse
CO2017001994A2 (es) Compuestos activos hacia bromodominios
GT201600249A (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
CR20170011A (es) Compuestos de heteroarilo para la inhibición de cinasa
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
EP3340988A4 (en) ION CHANNEL-INHIBITING COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES
BR112016025470A2 (pt) ?hdl terapêutico?
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112017004953A2 (pt) imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
CL2016002784A1 (es) Emulsión de agua en aceite para el cuidado de la piel
DK3137053T3 (da) Formuleringer af biologiske lægemidler til intravesikal instillation
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
IL268728A (en) Formulations of cannabinoids for the treatment of acne
MX392383B (es) Metodos para tratar afecciones oculares.
CL2016002779A1 (es) Composición para el cuidado de la piel
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
CL2019003571A1 (es) Lipido que comprende ácido docosapentanoico. (divisional solicitud 3351-2016)